Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000487893 | SCV000339676 | uncertain significance | not provided | 2016-02-12 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000487893 | SCV000574817 | uncertain significance | not provided | 2016-10-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000487893 | SCV000618626 | uncertain significance | not provided | 2017-07-10 | criteria provided, single submitter | clinical testing | The N2514S variant in the USH2A gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The N2514S variant is observed in 8/16,508 (0.048%) alleles from individuals of South Asian background in the ExAC dataset (Lek et al., 2016). The N2514S variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. However, this substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. We interpret N2514S as a variant of uncertain significance. |
Centre for Mendelian Genomics, |
RCV001196427 | SCV001367035 | uncertain significance | Usher syndrome type 2A | 2019-11-28 | criteria provided, single submitter | clinical testing | This variant was classified as: Uncertain significance. The available evidence on this variant's pathogenicity is insufficient or conflicting. The following ACMG criteria were applied in classifying this variant: PM1,PP3. |
Labcorp Genetics |
RCV000487893 | SCV001663409 | likely benign | not provided | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001196427 | SCV001453606 | uncertain significance | Usher syndrome type 2A | 2020-01-17 | no assertion criteria provided | clinical testing |